Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Crinetics Pharmaceuticals Inc.
Boston Scientific Corporation
University of Florida
Ohio State University Comprehensive Cancer Center
University of Iowa
University of Miami
Tanabe Pharma America, Inc.
Wren Laboratories LLC
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
Turning Point Therapeutics, Inc.
Hoffmann-La Roche
University of Roma La Sapienza